177lu-psma-617,cabazitaxel
emcure,sanofi,novartis
['biomarker', ' vision', 'cabazitaxel']
#asco22 key takeaways from vision and anzup 1603: 1. lu177-psma-617 more active than cabazitaxel, sequencing may not matter given os results
2. psma pet suv is an emerging biomarker, cutoff &gt;10 most likely to benefit. should prioritize these patients until drug shortages resolve 
Genitourinary oncologist 
#LevineCancerInstitute
@AtriumHealth
Views are my own
RT is not an endorsement